A European research team developing 3D bioprinting technology that could revolutionize medicine and food production is also navigating uncharted regulatory waters, exposing a gap between scientific innovation and the legal frameworks meant to govern it.
The five-year PRISM-LT project, funded by the European Union and scheduled to end in 2027, is developing engineered living materials, or ELMs: composite substances made partly or wholly of living cells, including genetically modified microorganisms. These materials can grow, respond, adapt, and self-repair in ways conventional materials cannot. Yet ELMs blur the boundaries between medicine, food, and biotechnology, so they don't fit neatly into any existing regulatory category across Europe.
The Science Works. The Rules Don't.
Massimo Vassalli, scientific coordinator of PRISM-LT and chair of bioengineering at the University of Glasgow, said the research aims to understand how living tissues form and recreate them in laboratories. The team builds tissues from tiny capsules containing living cells and a gel-like support material called bioink. Genetically modified microorganisms — yeast or bacteria — are programmed to detect when stem cells begin to differentiate, then release chemical signals called growth factors to guide them toward a desired tissue type.
Manufacturing takes from a few minutes to an hour. Maturation takes about three weeks, as stem cells develop into bone, fat, or muscle. The team can now produce roughly one square centimeter of thin tissue and is working toward a one-cubic-centimeter block.
The central scientific challenge, Vassalli said, is creating a "symbiotic relationship between two systems not designed to live together, like yeast and stem cells." He explained: "We have to create conditions suitable enough for both the yeast or bacteria and the stem cells while the latter differentiate." The process mirrors evolution itself, as single-celled organisms interact and evolve into the natural world we know.
But the researchers can't scale up this technology alone. They need legal certainty. ELMs combine living cells and, in some cases, genetically modified microorganisms. They're neither traditional medicines nor standard food products, and European regulatory bodies have no clear path to authorize them.
A Collaboration With European Authorities
Researchers are working directly with regulatory authorities, including the European Medicines Agency, alongside the European Innovation Council, to examine future rules and authorizations. Laura Martinelli, PRISM-LT project coordinator and executive director of In Society, a research organization based in Udine, Italy, emphasized the stakes: "We have to adopt a new attitude toward this technology. This collaboration helps us pave the way for the use of ELMs."
The PRISM-LT team is pursuing two immediate applications. One focuses on biomedical research: three-dimensional bone marrow models for studying drugs that treat diseases such as leukemia. The other targets cultivated meat — muscle-and-fat structures that reproduce the marbling responsible for natural meat's texture and flavor. Miniature tissue models could also mimic human organs for drug testing and personalized medicine.
For cultivated meat, the right distribution of adipose tissue matters for consumer acceptance. Martinelli said: "Thanks to our bioprinting technology, we can achieve the right texture in alternative meats, which gives us the opportunity to commercialize them." The researchers chose yeast rather than bacteria for this application because, she said, "It would be hard to explain to consumers that meat was made using bacteria."
The Distance Between Promise and Reality
Martinelli acknowledged the gap between current capability and real-world use. "We are still far from real-world applications. We focus on principles and mechanisms to see what is viable. However, we are already considering future challenges."
Vassalli described the progress in measured terms: "When we launched the project, we asked two key questions: is it viable? and is it scalable? Now we can say it is viable." Scaling up remains the next major hurdle, and it requires regulatory approval that doesn't yet exist.
The PRISM-LT project shows both the strength and fragility of EU-funded research infrastructure. The European Union is investing in frontier science that could address critical challenges in medicine and food security. Yet the regulatory framework that would let these innovations reach patients and consumers hasn't kept pace. The collaboration between researchers and authorities is encouraging, but it's also a tacit admission that European regulators are navigating this territory without a map.
Why This Matters:
The bioprinting project illustrates a structural challenge for the European Union: its capacity to fund cutting-edge research exceeds its capacity to regulate it. Innovations developed at public expense could be commercialized elsewhere — potentially in jurisdictions with weaker safety or ethical oversight. The gap also shows how sectoral regulation — separate frameworks for medicines, food, agriculture, and biotech — struggles when a single technology crosses all four fields.
This is precisely the kind of problem that requires EU-level coordination and harmonized rules. Without clear regulatory pathways developed now, European researchers and companies could find themselves locked out of markets they helped create. The absence of transparent, democratic regulatory frameworks also risks ceding legitimacy to critics who fear biotech innovation generally. A centre-left approach demands that such powerful technologies face strong public oversight, clear rules established through democratic process, and firm ethical guardrails — not regulatory silence that eventually gives way to crisis-driven restriction.